ES2896755T3 - Composiciones que comprenden polinucleótidos sintéticos que codifican proteínas relacionadas con CRISPR y ARNsg sintéticos y procedimientos de uso - Google Patents

Composiciones que comprenden polinucleótidos sintéticos que codifican proteínas relacionadas con CRISPR y ARNsg sintéticos y procedimientos de uso Download PDF

Info

Publication number
ES2896755T3
ES2896755T3 ES14823392T ES14823392T ES2896755T3 ES 2896755 T3 ES2896755 T3 ES 2896755T3 ES 14823392 T ES14823392 T ES 14823392T ES 14823392 T ES14823392 T ES 14823392T ES 2896755 T3 ES2896755 T3 ES 2896755T3
Authority
ES
Spain
Prior art keywords
synthetic
synthetic polynucleotide
sgrna
polynucleotide
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14823392T
Other languages
English (en)
Spanish (es)
Inventor
Stephen Hoge
Eric Huang
Tirtha Chakraborty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52280736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2896755(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Application granted granted Critical
Publication of ES2896755T3 publication Critical patent/ES2896755T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
ES14823392T 2013-07-11 2014-07-11 Composiciones que comprenden polinucleótidos sintéticos que codifican proteínas relacionadas con CRISPR y ARNsg sintéticos y procedimientos de uso Active ES2896755T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361844890P 2013-07-11 2013-07-11
US201361886545P 2013-10-03 2013-10-03
PCT/US2014/046434 WO2015006747A2 (en) 2013-07-11 2014-07-11 Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use.

Publications (1)

Publication Number Publication Date
ES2896755T3 true ES2896755T3 (es) 2022-02-25

Family

ID=52280736

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14823392T Active ES2896755T3 (es) 2013-07-11 2014-07-11 Composiciones que comprenden polinucleótidos sintéticos que codifican proteínas relacionadas con CRISPR y ARNsg sintéticos y procedimientos de uso

Country Status (17)

Country Link
US (2) US11027025B2 (enExample)
EP (2) EP3019619B1 (enExample)
JP (4) JP7019233B2 (enExample)
AU (2) AU2014287009B2 (enExample)
CA (1) CA2917348A1 (enExample)
CY (1) CY1124740T1 (enExample)
DK (1) DK3019619T3 (enExample)
ES (1) ES2896755T3 (enExample)
HR (1) HRP20211563T1 (enExample)
HU (1) HUE056760T2 (enExample)
LT (1) LT3019619T (enExample)
PL (1) PL3019619T3 (enExample)
PT (1) PT3019619T (enExample)
RS (1) RS62529B1 (enExample)
SI (1) SI3019619T1 (enExample)
SM (1) SMT202100691T1 (enExample)
WO (1) WO2015006747A2 (enExample)

Families Citing this family (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ700688A (en) 2009-12-01 2016-02-26 Shire Human Genetic Therapies Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
CN103906527B (zh) 2011-06-08 2020-07-10 川斯勒佰尔公司 Mrna递送的脂质纳米颗粒组合物和方法
EP3336082B1 (en) 2011-06-08 2020-04-15 Translate Bio, Inc. Cleavable lipids
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
JP6211054B2 (ja) 2012-03-29 2017-10-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 脂質誘導される中性ナノ粒子
BR112014024131A2 (pt) 2012-03-29 2017-07-25 Shire Human Genetic Therapies lipídios catiônicos ionizáveis
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
EP3884949A1 (en) 2012-06-08 2021-09-29 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
AU2013359199C1 (en) 2012-12-12 2021-06-17 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
ES2701749T3 (es) 2012-12-12 2019-02-25 Broad Inst Inc Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos
AU2014207618A1 (en) 2013-01-16 2015-08-06 Emory University Cas9-nucleic acid complexes and uses related thereto
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
BR112015022855A2 (pt) 2013-03-14 2017-11-07 Shire Human Genetic Therapies composições e método para produção de um anticorpo in vitro
EP2968586B1 (en) 2013-03-14 2018-07-25 Translate Bio, Inc. Cftr mrna compositions and related methods and uses
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
ES2708561T3 (es) 2013-03-14 2019-04-10 Translate Bio Inc Métodos para la purificación de ARN mensajero
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
RS57316B1 (sr) 2013-03-15 2018-08-31 Translate Bio Inc Sinergističko poboljšanje isporuke nukleinskih kiselina pomoću mešavina formulacija
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
EP3725885A1 (en) 2013-06-17 2020-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
AU2014281026B2 (en) 2013-06-17 2020-05-28 Massachusetts Institute Of Technology Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
RU2716421C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка, применение и применения в терапии систем crispr-cas и композиций для целенаправленного воздействия на нарушения и заболевания с использованием вирусных компонентов
SG11201510284XA (en) 2013-06-17 2016-01-28 Broad Inst Inc Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
WO2014204725A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
SMT202100691T1 (it) 2013-07-11 2022-01-10 Modernatx Inc Composizioni 5 comprendenti polinucleotidi sintetici che codificano proteine correlate a crispr e sgrna sintetici e metodi d'uso
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US20160201072A1 (en) 2013-08-22 2016-07-14 Pioneer Hi-Bred International, Inc. Genome modification using guide polynucleotide/cas endonuclease systems and methods of use
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
EP3988649B1 (en) 2013-09-18 2024-11-27 Kymab Limited Methods, cells and organisms
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051169A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
KR101988552B1 (ko) 2013-10-22 2019-09-25 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna의 전달을 위한 지질 제형
EP4276176A3 (en) 2013-10-22 2024-01-10 Translate Bio, Inc. Mrna therapy for argininosuccinate synthetase deficiency
EP3060258A1 (en) 2013-10-22 2016-08-31 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
EP3060671B1 (en) 2013-10-22 2021-12-29 Translate Bio, Inc. Cns delivery of mrna and uses thereof
EP4372090A3 (en) 2013-11-07 2024-08-07 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
EP3080261B1 (en) 2013-12-12 2019-05-22 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
EP4219699A1 (en) 2013-12-12 2023-08-02 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
KR20250068794A (ko) 2013-12-12 2025-05-16 더 브로드 인스티튜트, 인코퍼레이티드 게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
AU2014362245A1 (en) 2013-12-12 2016-06-16 Massachusetts Institute Of Technology Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
KR102209636B1 (ko) 2014-02-11 2021-01-29 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 Crispr 이용의 다중화된 게놈 조작
PT3134131T (pt) 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
CA2944800A1 (en) 2014-04-25 2015-10-29 Shire Human Genetic Therapies, Inc. Methods for purification of messenger rna
EP3148552B1 (en) 2014-05-30 2019-07-31 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
KR102511554B1 (ko) 2014-06-24 2023-03-16 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
CA2953265C (en) 2014-07-02 2023-09-26 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
JP2017522028A (ja) 2014-07-16 2017-08-10 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 環状ポリヌクレオチド
EP4079847A1 (en) 2014-07-30 2022-10-26 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US9943595B2 (en) 2014-12-05 2018-04-17 Translate Bio, Inc. Messenger RNA therapy for treatment of articular disease
EP3985115A1 (en) 2014-12-12 2022-04-20 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094880A1 (en) * 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
JP6929791B2 (ja) 2015-02-09 2021-09-01 デューク ユニバーシティ エピゲノム編集のための組成物および方法
US12129471B2 (en) 2015-02-23 2024-10-29 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of human genetic diseases including hemoglobinopathies
WO2016135558A2 (en) 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
DK3064587T3 (da) 2015-03-06 2019-09-30 Leibniz Inst Fuer Pflanzenbiochemie Ipb Bibliotek af syntetiske promotere til koordineret genekspression i eukaryotiske celler eller organismer
JP6895892B2 (ja) 2015-03-19 2021-06-30 トランスレイト バイオ， インコーポレイテッド ポンペ病のｍＲＮＡ治療
WO2016154596A1 (en) * 2015-03-25 2016-09-29 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
KR102648489B1 (ko) 2015-04-06 2024-03-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
EP3087974A1 (en) * 2015-04-29 2016-11-02 Rodos BioTarget GmbH Targeted nanocarriers for targeted drug delivery of gene therapeutics
JP7030522B2 (ja) * 2015-05-11 2022-03-07 エディタス・メディシン、インコーポレイテッド 幹細胞における遺伝子編集のための最適化ｃｒｉｓｐｒ／ｃａｓ９システムおよび方法
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
WO2016197133A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics, Inc. Delivering crispr therapeutics with lipid nanoparticles
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
MX392008B (es) 2015-06-18 2025-03-21 Broad Inst Inc Mutaciones de la enzima crispr que reducen los efectos fuera del blanco
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
CA2990699A1 (en) 2015-06-29 2017-01-05 Ionis Pharmaceuticals, Inc. Modified crispr rna and modified single crispr rna and uses thereof
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
WO2017024047A1 (en) * 2015-08-03 2017-02-09 Emendobio Inc. Compositions and methods for increasing nuclease induced recombination rate in cells
CN105002198B (zh) * 2015-08-07 2018-07-06 北京蛋白质组研究中心 用于培育表达人血清白蛋白的转基因猪的成套产品及其应用
DK3350333T3 (da) 2015-09-17 2022-01-31 Modernatx Inc Polynukleotider, der indeholder en stabiliserende haleregion
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
WO2017053312A1 (en) * 2015-09-21 2017-03-30 The Regents Of The University Of California Compositions and methods for target nucleic acid modification
JP2018534258A (ja) * 2015-09-29 2018-11-22 アジェノビア コーポレーション 潜伏ウイルスの転写制御のための組成物および方法
JP6990176B2 (ja) 2015-10-05 2022-02-03 モデルナティエックス インコーポレイテッド メッセンジャーリボ核酸薬物の治療投与のための方法
EP4089175A1 (en) * 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
AU2016338559B2 (en) 2015-10-14 2022-11-24 Translate Bio, Inc. Modification of RNA-related enzymes for enhanced production
WO2017068077A1 (en) 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
EP4349404A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and uses thereof
ES2942309T3 (es) 2015-11-04 2023-05-31 Vertex Pharma Materiales y métodos para el tratamiento de hemoglobinopatías
EA201891317A3 (ru) 2015-11-30 2019-04-30 Дьюк Юниверсити Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
KR102698595B1 (ko) * 2015-12-18 2024-08-23 다니스코 유에스 인크. 중합효소 ii(pol-ii) 기반의 가이드 rna 발현을 위한 방법 및 조성물
WO2017131237A1 (ja) * 2016-01-30 2017-08-03 株式会社ボナック 人工単一ガイドｒｎａ及びその用途
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
CN109714954A (zh) 2016-04-02 2019-05-03 全国儿童医院研究所 用于组织特异性表达的修饰的u6启动子系统
CN109072223B (zh) 2016-04-08 2022-10-21 川斯勒佰尔公司 多聚体编码核酸及其用途
EP3443081A4 (en) 2016-04-13 2019-10-30 Duke University CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
CN109312313A (zh) 2016-06-13 2019-02-05 川斯勒佰尔公司 用于治疗鸟氨酸转氨甲酰酶缺乏症的信使rna疗法
JP7160465B2 (ja) 2016-06-20 2022-10-25 キージーン ナムローゼ フェンノートシャップ 植物細胞における標的化ｄｎａ変更のための方法
DK3474669T3 (da) 2016-06-24 2022-06-27 Univ Colorado Regents Fremgangsmåde til generering af stregkodede kombinatoriske biblioteker
US12385034B2 (en) 2016-06-24 2025-08-12 Modernatx, Inc. Methods and apparatus for filtration
US20190256830A1 (en) * 2016-06-27 2019-08-22 Kyoto University Method for cell-specifically controlling nuclease
US10927383B2 (en) * 2016-06-30 2021-02-23 Ethris Gmbh Cas9 mRNAs
JP2019520829A (ja) 2016-07-07 2019-07-25 ルビウス セラピューティクス， インコーポレイテッド 外来性ｒｎａを発現する治療的細胞系に関連する組成物及び方法
US12214056B2 (en) 2016-07-19 2025-02-04 Duke University Therapeutic applications of CPF1-based genome editing
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
SG11201901306XA (en) * 2016-08-19 2019-03-28 Toolgen Inc Artificially engineered angiogenesis regulatory system
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
US11306305B2 (en) 2016-09-23 2022-04-19 Board Of Trustees Of Southern Illinois University Tuning CRISPR/Cas9 activity with chemically modified nucleotide substitutions
US11566237B2 (en) * 2016-09-23 2023-01-31 University Of Massachusetts Silencing of DUX4 by recombinant gene editing complexes
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
WO2018115389A1 (en) 2016-12-22 2018-06-28 Keygene N.V. Methods of targeted genetic alteration in plant cells
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
US12215329B2 (en) 2017-02-15 2025-02-04 Keygene N.V. Methods of targeted genetic alteration in plant cells
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
GB2575930A (en) 2017-03-23 2020-01-29 Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
KR102842382B1 (ko) 2017-03-24 2025-08-04 큐어백 에스이 Crispr-연관 단백질을 암호화하는 핵산 및 이의 용도
CN110678548A (zh) 2017-03-31 2020-01-10 埃吉诺维亚公司 抗病毒治疗剂
KR101852718B1 (ko) * 2017-04-04 2018-05-18 주식회사 제네웰 외과수술 후 절개부위 통증 감소를 위한 키트
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
CN111212905A (zh) 2017-08-18 2020-05-29 摩登纳特斯有限公司 Rna聚合酶变体
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
CA3073211A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
JP2020533972A (ja) 2017-09-08 2020-11-26 キージーン ナムローゼ フェンノートシャップ バランスがとれたインデル
KR102822306B1 (ko) 2017-09-29 2025-06-19 인텔리아 테라퓨틱스, 인크. 게놈 편집을 위한 폴리뉴클레오티드, 조성물 및 방법
EP3688162B1 (en) * 2017-09-29 2024-03-06 Intellia Therapeutics, Inc. Formulations
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. USES OF BASIC EDITORS ADENOSINE
BR112020004351A2 (pt) 2017-10-19 2020-09-08 Curevac Ag moléculas de ácido nucleico artificial
WO2019088496A2 (ko) 2017-10-31 2019-05-09 주식회사 에이치유비바이오텍 내인성 폴리펩타이드 생산을 위한 재조합 세포 및 방법
WO2019087113A1 (en) 2017-11-01 2019-05-09 Novartis Ag Synthetic rnas and methods of use
WO2019116346A1 (en) 2017-12-15 2019-06-20 Novartis Ag Polya tail length analysis of rna by mass spectrometry
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
MA51306A (fr) 2017-12-20 2020-10-28 Translate Bio Inc Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
WO2019150203A1 (en) 2018-02-05 2019-08-08 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
US20220010293A1 (en) 2018-02-23 2022-01-13 Pioneer Hi-Bred International, Inc. Novel cas9 orthologs
US20210254049A1 (en) * 2018-04-20 2021-08-19 Cellino Biotech, Inc. Directed cell fate specification and targeted maturation
KR102852347B1 (ko) 2018-05-11 2025-09-01 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 아미노산을 치환하는 방법
CA3097912A1 (en) * 2018-05-15 2019-11-21 Translate Bio, Inc. Subcutaneous delivery of messenger rna
CN108642055B (zh) * 2018-05-17 2021-12-03 吉林大学 能有效编辑猪miR-17-92基因簇的sgRNA
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
CA3106162A1 (en) * 2018-07-13 2020-01-16 Allele Biotechnology And Pharmaceuticals, Inc. Methods of achieving high specificity of genome editing
WO2020018558A1 (en) * 2018-07-17 2020-01-23 Aronora, Inc. Methods for safely reducing thrombopoietin
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
EP4509118A3 (en) 2018-09-19 2025-05-14 ModernaTX, Inc. High-purity peg lipids and uses thereof
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
EP3874048A1 (en) 2018-11-01 2021-09-08 Keygene N.V. Dual guide rna for crispr/cas genome editing in plants cells
WO2020097083A1 (en) 2018-11-06 2020-05-14 Cellino Biotech, Inc. Systems for cell control
EP3883592A1 (en) 2018-11-21 2021-09-29 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
CN113166744B (zh) 2018-12-14 2025-02-07 先锋国际良种公司 用于基因组编辑的新颖crispr-cas系统
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020163379A1 (en) 2019-02-05 2020-08-13 Emendobio Inc. Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
MA55037A (fr) 2019-02-20 2021-12-29 Modernatx Inc Variants d'arn polymérase pour le coiffage co-transcriptionnel
EP3938507A4 (en) 2019-03-11 2023-02-22 ModernaTX, Inc. PROCEDURE FOR IN VITRO FED BATCH TRANSCRIPTION
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
DE112020001342T5 (de) 2019-03-19 2022-01-13 President and Fellows of Harvard College Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2021072328A1 (en) 2019-10-10 2021-04-15 The Broad Institute, Inc. Methods and compositions for prime editing rna
US11827926B2 (en) 2020-03-23 2023-11-28 President And Fellows Of Harvard College Methods and compositions for the diagnosis and treatment of COVID 19
CA3176545A1 (en) 2020-04-22 2021-10-28 President And Fellows Of Harvard College Isothermal methods, compositions, kits, and systems for detecting nucleic acids
GB2614813B (en) 2020-05-08 2025-05-07 Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
AU2021271317A1 (en) 2020-05-15 2023-01-19 Crispr Therapeutics Ag Messenger RNA encoding Cas9 for use in genome-editing systems
JPWO2022004765A1 (enExample) * 2020-06-30 2022-01-06
EP4225946A4 (en) 2020-10-06 2024-10-30 President And Fellows Of Harvard College METHODS, COMPOSITIONS, KITS AND SYSTEMS FOR SIGNAL-BASED DETECTION OF NEUTRALIZATION TARGETS
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
CN112877368B (zh) * 2021-01-25 2023-05-16 华中农业大学 一种用于成熟植物的基因编辑系统及基因编辑方法
WO2022171783A1 (en) 2021-02-11 2022-08-18 Koninklijke Nederlandse Akademie Van Wetenschappen Curing disease by transcription regulatory gene editing
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
US20240384277A1 (en) 2021-06-15 2024-11-21 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
WO2023185697A2 (en) 2022-03-29 2023-10-05 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treatment of transthyretin amyloidosis
CN119731321A (zh) 2022-06-24 2025-03-28 图恩疗法股份有限公司 通过靶向基因阻遏减少低密度脂蛋白的组合物、系统和方法
WO2024023067A1 (en) 2022-07-25 2024-02-01 Koninklijke Nederlandse Akademie Van Wetenschappen Curing disease by transcription regulatory gene editing
WO2024026254A1 (en) 2022-07-26 2024-02-01 Modernatx, Inc. Engineered polynucleotides for temporal control of expression
CN119948162A (zh) 2022-09-22 2025-05-06 锐正基因(苏州)有限公司 用于治疗高胆固醇血症和/或心血管疾病的组合物和方法
AU2024215535A1 (en) 2023-01-31 2025-08-28 Synplogen Co., Ltd. Artificially synthesized nucleic acid for increasing protein expression
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2025108148A1 (zh) * 2023-11-24 2025-05-30 山东舜丰生物科技有限公司 一种活性改善的cas蛋白及其应用
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome
CN120290555A (zh) * 2024-12-04 2025-07-11 中国农业科学院北京畜牧兽医研究所 一种基于CRISPR/Cas12a技术检测双等位基因编辑细胞的方法

Family Cites Families (399)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5927900A (ja) 1982-08-09 1984-02-14 Wakunaga Seiyaku Kk 固定化オリゴヌクレオチド
FR2540122B1 (fr) 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4605735A (en) 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4824941A (en) 1983-03-10 1989-04-25 Julian Gordon Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5258506A (en) 1984-10-16 1993-11-02 Chiron Corporation Photolabile reagents for incorporation into oligonucleotide chains
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4762779A (en) 1985-06-13 1988-08-09 Amgen Inc. Compositions and methods for functionalizing nucleic acids
US5317098A (en) 1986-03-17 1994-05-31 Hiroaki Shizuya Non-radioisotope tagging of fragments
JPS638396A (ja) 1986-06-30 1988-01-14 Wakunaga Pharmaceut Co Ltd ポリ標識化オリゴヌクレオチド誘導体
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5525465A (en) 1987-10-28 1996-06-11 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates and methods of production and applications of the same
DE3738460A1 (de) 1987-11-12 1989-05-24 Max Planck Gesellschaft Modifizierte oligonukleotide
US5082830A (en) 1988-02-26 1992-01-21 Enzo Biochem, Inc. End labeled nucleotide probe
US5109124A (en) 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
US5262536A (en) 1988-09-15 1993-11-16 E. I. Du Pont De Nemours And Company Reagents for the preparation of 5'-tagged oligonucleotides
US5759802A (en) 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5599923A (en) 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5451463A (en) 1989-08-28 1995-09-19 Clontech Laboratories, Inc. Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5254469A (en) 1989-09-12 1993-10-19 Eastman Kodak Company Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
JP3127158B2 (ja) 1989-10-05 2001-01-22 オプテイン，インコーポレイティド 新規の遺伝子及びポリペチドの無細胞合成並びに単離
ATE190981T1 (de) 1989-10-24 2000-04-15 Isis Pharmaceuticals Inc 2'-modifizierte nukleotide
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5292873A (en) 1989-11-29 1994-03-08 The Research Foundation Of State University Of New York Nucleic acids labeled with naphthoquinone probe
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US7037646B1 (en) 1990-01-11 2006-05-02 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US6783931B1 (en) 1990-01-11 2004-08-31 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
WO1991013080A1 (en) 1990-02-20 1991-09-05 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
CA2028849A1 (en) 1990-03-08 1991-09-09 Michinao Mizugaki Monoclonal antibodies, assay method, reagent kit, sarching method and drug missiles using them
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (es) 1990-05-11 1998-08-01 Microprobe Corp Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5688941A (en) 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
EP0556301B1 (en) 1990-11-08 2001-01-10 Hybridon, Inc. Incorporation of multiple reporter groups on synthetic oligonucleotides
US5426180A (en) 1991-03-27 1995-06-20 Research Corporation Technologies, Inc. Methods of making single-stranded circular oligonucleotides
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5371241A (en) 1991-07-19 1994-12-06 Pharmacia P-L Biochemicals Inc. Fluorescein labelled phosphoramidites
US5437976A (en) 1991-08-08 1995-08-01 Arizona Board Of Regents, The University Of Arizona Multi-domain DNA ligands bound to a solid matrix for protein and nucleic acid affinity chromatography and processing of solid-phase DNA
DE59208572D1 (de) 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
DK0618925T4 (da) 1991-12-24 2012-07-09 Isis Pharmaceuticals Inc Antisense-oligonukleotider
US5595726A (en) 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
US5272250A (en) 1992-07-10 1993-12-21 Spielvogel Bernard F Boronated phosphoramidate compounds
DE69329785D1 (de) 1992-09-17 2001-02-01 Dsm Nv Hefederivate und Verfahren zum Verbessern der Brotqualität
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
JPH08508492A (ja) 1993-03-30 1996-09-10 スターリング ウィンスロップ インコーポレイティド 非環式ヌクレオシド類似体及びそれらを含むオリゴヌクレオチド配列
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US6294664B1 (en) 1993-07-29 2001-09-25 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
FR2733762B1 (fr) 1995-05-02 1997-08-01 Genset Sa Methode de couplage specifique de la coiffe de l'extremite 5' d'un fragment d'arnm et preparation d'arnm et d'adnc complet
US5808039A (en) 1995-10-18 1998-09-15 Beckman Instruments, Inc. 2'-OMe CAC phosphoramidite and methods for preparation and use thereof
US5871697A (en) 1995-10-24 1999-02-16 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
US6022737A (en) 1995-11-02 2000-02-08 Amgen Inc. Formulations for non-viral in vivo transfection in the lungs
US5789578A (en) 1996-01-11 1998-08-04 Massey University Methods for the preparation of resins with ligands attached thereto through a linking group comprising sulfide, sulfoxide or sulfone functionality
US7291463B2 (en) 1996-01-23 2007-11-06 Affymetrix, Inc. Nucleic acid labeling compounds
WO1998000194A2 (en) 1996-06-28 1998-01-08 Sontra Medical, L.P. Ultrasound enhancement of transdermal transport
US6475388B1 (en) 1996-11-13 2002-11-05 Transgenomic, Inc. Method and system for RNA analysis by matched ion polynucleotide chromatography
US6576752B1 (en) 1997-02-14 2003-06-10 Isis Pharmaceuticals, Inc. Aminooxy functionalized oligomers
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
GB2324370B (en) 1997-04-14 1999-03-03 Stuart Harbron Detection of hybrid double-stranded DNA with antibody after enzyme degradation of excess single-standed DNA
US5989911A (en) 1997-05-09 1999-11-23 University Of Massachusetts Site-specific synthesis of pseudouridine in RNA
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6303378B1 (en) 1997-10-24 2001-10-16 Valentis, Inc. Methods for preparing polynucleotide transfection complexes
US6548633B1 (en) 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides
US6517869B1 (en) 1997-12-12 2003-02-11 Expression Genetics, Inc. Positively charged poly(alpha-(omega-aminoalkyl)lycolic acid) for the delivery of a bioactive agent via tissue and cellular uptake
AU1819499A (en) 1997-12-12 1999-06-28 Samyang Corporation Positively-charged poly{alpha-(omega-aminoalkyl)glycolic acid} for the delivery of a bioactive agent via tissue and cellular uptake
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
US8287483B2 (en) 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
EP1045714A1 (en) 1998-01-08 2000-10-25 Sontra Medical, L.P. Sonophoretic enhanced transdermal transport
US5955310A (en) 1998-02-26 1999-09-21 Novo Nordisk Biotech, Inc. Methods for producing a polypeptide in a bacillus cell
ATE411049T1 (de) 1998-05-20 2008-10-15 Expression Genetics Inc Laktose oder galaktose-polyethylen glykol- gepfropfte poly-l-lysin als genträger
EP1117720A4 (en) 1998-07-13 2001-11-14 Expression Genetics Inc POLYESTER POLY-L-LYSINE ANALOG USED AS A BIODEGRADABLE SOLUBLE GENE CONVEYOR
US6248268B1 (en) 1998-11-16 2001-06-19 Xc Corporation Process of making microparticles of a thermally-gelled polysaccharide
US20040171980A1 (en) 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6270970B1 (en) 1999-05-14 2001-08-07 Promega Corporation Mixed-bed solid phase and its use in the isolation of nucleic acids
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
EP1541690A3 (en) 1999-09-09 2005-07-27 CureVac GmbH Transfer of mRNA using polycationic compounds
AU767646B2 (en) 1999-09-10 2003-11-20 Geron Corporation Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
US6511832B1 (en) 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
CA2325169A1 (en) 1999-12-03 2001-06-03 Ndsu Research Foundation Somatostatins and method
CA2392757A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences Inc. Nucleic acids, proteins, and antibodies
CA2395811A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
EP1276702A2 (en) 2000-03-31 2003-01-22 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
WO2002000677A1 (en) 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2421122A1 (en) 2000-09-01 2002-03-07 Hyseq, Inc. Novel nucleic acids and polypeptides
US20040142474A1 (en) 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US6521411B2 (en) 2000-09-28 2003-02-18 Transgenomic, Inc. Method and system for the preparation of cDNA
US6998484B2 (en) 2000-10-04 2006-02-14 Santaris Pharma A/S Synthesis of purine locked nucleic acid analogues
WO2002044399A2 (en) 2000-11-28 2002-06-06 Rosetta Inpharmatics, Inc. In vitro transcription method for rna amplification
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20040142433A1 (en) 2001-02-02 2004-07-22 Padgett Hal S. Polynucleotide sequence variants
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US7211654B2 (en) 2001-03-14 2007-05-01 Regents Of The University Of Michigan Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports
US20050235369A1 (en) 2001-03-28 2005-10-20 Yen Choo Gene regulation II
DE50211110D1 (de) 2001-04-21 2007-12-06 Curevac Gmbh INJEKTIONSGERÄT FÜR mRNA APPLIKATION
EP1383887A4 (en) 2001-05-03 2004-07-07 Rensselaer Polytech Inst NEW PROCEDURES FOR DIRECTED EVOLUTION
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP1903054A3 (de) 2001-06-05 2008-07-23 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP2428569B1 (en) 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
AU2002338926B2 (en) 2001-11-05 2007-05-24 Janssen Pharmaceutica N.V. Method for the in vitro synthesis of short double stranded RNAs
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
US20040076978A1 (en) 2001-11-14 2004-04-22 Catherine Verfaillie Method to identify genes associated with chronic myelogenous leukemia
WO2003051881A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
WO2003054166A2 (en) 2001-12-20 2003-07-03 Incyte Genomics, Inc. Nucleotide polymorphisms associated with osteoarthritis
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
EP1487999B1 (en) 2002-03-15 2006-12-27 Epigenomics AG Discovery and diagnostic methods using 5-methylcytosine dna glycosylase
US7374930B2 (en) 2002-05-21 2008-05-20 Expression Genetics, Inc. GLP-1 gene delivery for the treatment of type 2 diabetes
US20050053942A1 (en) 2002-06-24 2005-03-10 Sakari Kauppinen Methods and systems for detection and isolation of a nucleotide sequence
US20040220127A1 (en) 2002-08-09 2004-11-04 Paul Sternberg Methods and compositions relating to 5'-chimeric ribonucleic acids
EP1552018B1 (en) 2002-08-12 2009-07-01 New England Biolabs, Inc. Methods and compositions relating to gene silencing
US7344858B2 (en) 2002-08-31 2008-03-18 Cj Corp Glycosylated human granulocyte colony-stimulating factor (G-CSF) isoform
WO2004029196A2 (en) 2002-09-24 2004-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of determining the effect of an agent on diploid cells and/or on the pattern of expression of polypeptides expressed therewith
WO2004042054A1 (ja) 2002-10-23 2004-05-21 Hubit Genomix, Inc. 歯周疾患に関連する遺伝的多型
CA2504481A1 (en) 2002-10-30 2004-05-21 Pointilliste, Inc. Systems for capture and analysis of biological particles and methods using the systems
KR101123489B1 (ko) 2003-01-16 2012-03-28 이데라 파마슈티칼즈, 인코포레이티드 개질된 면역자극성 디뉴클레오티드를 이용한 올리고뉴클레오티드-기재 화합물의 면역자극 특성의 조절
AU2004222451A1 (en) 2003-03-20 2004-09-30 Keiichi Fukuda Combined use of G-CSF and factors having angiogenic action
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US20060182736A1 (en) 2003-06-10 2006-08-17 Kim Jin-Soo Transducible dna-binding proteins
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2005028617A2 (en) 2003-09-12 2005-03-31 Cedars-Sinai Medical Center Antisense inhibition of laminin-8 expression to inhibit human gliomas
CA2536139A1 (en) 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
EP2314689A3 (en) 2003-12-03 2012-12-19 Coda Therapeutics (NZ) Ltd Antisense compounds targeted to connexins and methods of use thereof
KR20070052694A (ko) 2004-01-09 2007-05-22 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 유전자 발현을 위한 세포-유형-특이적 패턴
EP1713514B1 (en) 2004-01-28 2021-11-24 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US20080103053A1 (en) 2005-11-22 2008-05-01 Helicos Biosciences Corporation Methods and compositions for sequencing a nucleic acid
US7527947B2 (en) 2004-06-14 2009-05-05 Novozymes A/S Signal peptide for producing a polypeptide
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
JP5192234B2 (ja) 2004-08-10 2013-05-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 化学修飾オリゴヌクレオチド
CN101048181A (zh) 2004-08-13 2007-10-03 巴里·J·马沙尔 细菌递送系统
JP4903146B2 (ja) 2004-08-16 2012-03-28 イミューン ディズィーズ インスティテュート インコーポレイテッド Ｒｎａ干渉を送達する方法およびその使用法
US7361903B2 (en) 2004-09-01 2008-04-22 Koninklijke Philips Electronics N.V. Image system with non-circular patient aperture
CA2583375C (en) 2004-09-02 2013-01-15 Yale University Regulation of oncogenes by micrornas
US8057821B2 (en) 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
ATE540110T1 (de) 2004-11-11 2012-01-15 Modular Genetics Inc Oligonukleotid-leiterkonstruktion und system zur erzeugung von molekularer vielfalt
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
EP1856179B1 (en) 2004-12-10 2013-05-15 Kala Pharmaceuticals, Inc. Functionalized poly (ether-anhydride) block copolymers
FR2880345A1 (fr) 2004-12-30 2006-07-07 Adisseo Ireland Ltd Synthese et applications de l'acide 2-oxo-4-methylthiobutyrique, ses tels et ses derives
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2007086881A2 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
EP1907590B1 (en) 2005-06-30 2012-09-19 Archemix LLC T7 rna polymerase and methods for the generation of fully 2'-modified nucleic acid transcripts
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
WO2007024778A2 (en) 2005-08-22 2007-03-01 Applera Corporation Device, system and method for depositing processed immiscible-fluid-discrete-volumes
LT2578685T (lt) 2005-08-23 2019-06-10 The Trustees Of The University Of Pennsylvania Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9157066B2 (en) 2005-12-13 2015-10-13 The Trustees Of The University Of Pennsylvania Transcriptome transfer produces cellular phenotype conversion
US20070161031A1 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
WO2007092182A2 (en) 2006-01-26 2007-08-16 University Of Massachusetts Rna interference agents for therapeutic use
AU2007211080B9 (en) 2006-01-27 2012-05-03 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
CA2649325C (en) 2006-04-14 2019-01-08 Epicentre Technologies Corporation Kits and methods for generating 5' capped rna
US8163535B2 (en) 2006-06-26 2012-04-24 Blood Cell Storage, Inc. Devices and processes for nucleic acid extraction
DE602007013559D1 (de) 2006-07-07 2011-05-12 Univ Aarhus Nanoteilchen zur abgabe von nukleinsäure
WO2008016473A2 (en) 2006-07-28 2008-02-07 Applera Corporation Dinucleotide mrna cap analogs
WO2008017473A2 (en) 2006-08-08 2008-02-14 Gunther Hartmann Structure and use of 5' phosphate oligonucleotides
ATE498393T1 (de) 2006-09-08 2011-03-15 Univ Johns Hopkins Zusammensetzungen zur transportintensivierung durch die schleimhaut
GB2445441B (en) 2006-09-26 2010-06-30 Ge Healthcare Bio Sciences Nucleic acid purification method
WO2008045505A2 (en) 2006-10-10 2008-04-17 Xenomics, Inc. Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
CA2673029C (en) 2006-12-22 2017-03-28 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP2131848A4 (en) 2007-02-16 2012-06-27 Merck Sharp & Dohme COMPOSITIONS AND METHODS FOR REINFORCED ACTIVITY OF BIOLOGICAL ACTIVE MOLECULES
EP2135080A4 (en) 2007-03-08 2010-12-01 Switchgear Genomics FUNCTIONAL NETWORKS FOR THE CHARACTERIZATION OF TREATMENT OF REGULATORY ELEMENTS IN NON-TRANSLATED REGIONS OF GENES
GB0706243D0 (en) 2007-03-30 2007-05-09 Univ Southampton Modified nucleic acids
JP2010525881A (ja) 2007-04-27 2010-07-29 エコー セラピューティクス， インコーポレイテッド 被検体の検知または経皮的薬物送達のための皮膚透過装置
US7682789B2 (en) 2007-05-04 2010-03-23 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
US20080311140A1 (en) 2007-05-29 2008-12-18 Baylor College Of Medicine Antigen specific immunosuppression by dendritic cell therapy
US20090042825A1 (en) 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009042971A2 (en) * 2007-09-26 2009-04-02 Intrexon Corporation Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression
ES2647538T3 (es) 2007-09-28 2017-12-22 Pfizer Inc. Direccionamiento a células de cáncer usando nanopartículas
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
EP2617828B1 (en) 2007-12-10 2014-09-24 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of factor VII gene
WO2009074968A2 (en) 2007-12-12 2009-06-18 Ecole Polytechnique Federale De Lausanne (Epfl) Method for predicting the efficacy of cancer therapy
ES2537703T3 (es) 2008-01-31 2015-06-11 Curevac Gmbh Ácidos nucleicos que comprenden la fórmula (NuGlXmGnNv)a y sus derivados como agentes/adyuvantes inmunoestimuladores
WO2009108891A2 (en) 2008-02-29 2009-09-03 Egen, Inc. Modified poloxamers for gene expression and associated methods
WO2009114854A1 (en) 2008-03-14 2009-09-17 Egen, Inc. Biodegradable cross-linked branched poly (alkylene imines)
WO2009120878A2 (en) 2008-03-26 2009-10-01 Alnylam Pharmaceuticals, Inc. Non-natural ribonucleotides, and methods of use thereof
PL2279254T3 (pl) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
WO2009147519A1 (en) 2008-06-06 2009-12-10 Centre National De La Recherche Scientifique - Cnrs- Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
PT2774608T (pt) 2008-06-16 2020-01-17 Pfizer Nanopartículas poliméricas carregadas com fármaco e métodos de produção e utilização das mesmas
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
WO2010005740A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
WO2010005725A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US20100009424A1 (en) 2008-07-14 2010-01-14 Natasha Forde Sonoporation systems and methods
CN102144030B (zh) 2008-07-24 2016-05-04 明治制果药业株式会社 啶南平a生物合成基因
EP2304026A4 (en) 2008-07-31 2013-12-18 Belrose Pharma Inc NANOPARTICLE COMPOSITIONS FOR A NUCLEIC ACID DELIVERY SYSTEM
ES2561812T3 (es) 2008-08-01 2016-03-01 Kyowa Hakko Kirin Co., Ltd. Composición para inhibir la expresión de un gen diana
WO2010017510A1 (en) 2008-08-07 2010-02-11 University Of Southern California A system for synergistic expression of multiple small functional rna elements
WO2010021865A1 (en) 2008-08-18 2010-02-25 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
US20100075072A1 (en) 2008-09-25 2010-03-25 Tsung-Wei Chen Decorative structure of tree-shaped bells
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
MX2011004859A (es) 2008-11-07 2011-08-03 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
WO2010075072A2 (en) 2008-12-15 2010-07-01 Bind Biosciences Long circulating nanoparticles for sustained release of therapeutic agents
US8367330B2 (en) 2008-12-22 2013-02-05 Quest Diagnostics Investments Incorporated Methods for detecting TCR-gamma gene rearrangement
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
US8669085B2 (en) 2009-02-05 2014-03-11 Ut-Battelle, Llc Transformation of gram positive bacteria by sonoporation
KR101906392B1 (ko) 2009-03-20 2018-10-10 씨엘에스엔 래버러토리스, 인코퍼레이티드 폴리아민 유도체
EP2411418B1 (en) 2009-03-24 2018-09-12 Council of Scientific & Industrial Research Process for the preparation of agarose polymer from seaweed extractive
CN102448977A (zh) 2009-04-09 2012-05-09 加州理工学院 用于聚合物合成的多路复用位点
EP2421561A2 (en) 2009-04-21 2012-02-29 Selecta Biosciences, Inc. Immunonanotherapeutics providing a th1-biased response
US20100273220A1 (en) * 2009-04-22 2010-10-28 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
WO2010127029A1 (en) 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
SG10201911942UA (en) 2009-05-05 2020-02-27 Muthiah Manoharan Lipid compositions
CN102481375B (zh) 2009-05-27 2017-06-06 西莱克塔生物科技公司 具有不同释放速率的纳米载体加工组分
SG10201912450XA (en) 2009-06-10 2020-03-30 Arbutus Biopharma Corp Improved lipid formulation
US8765370B2 (en) 2009-06-11 2014-07-01 Scinopharm Taiwan, Ltd Inhibition-based high-throughput screen strategy for cell clones
US20120164189A1 (en) 2009-07-07 2012-06-28 Balu-Iyer Sathy V Lipidic Compositions for Induction of Immune Tolerance
US9512164B2 (en) 2009-07-07 2016-12-06 Alnylam Pharmaceuticals, Inc. Oligonucleotide end caps
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
KR20140119197A (ko) 2009-07-31 2014-10-08 에트리스 게엠베하 단백질 발현을 위한 비변형된 뉴클레오티드 및 변형된 뉴클레오티드의 조합을 가진 ｒｎａ
US8598327B2 (en) 2009-08-18 2013-12-03 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
EP3072881A1 (en) 2009-08-20 2016-09-28 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
GB2473814B (en) 2009-09-16 2014-06-11 Spheritech Ltd Hollow particulate support
US20120253032A1 (en) 2009-10-08 2012-10-04 Merck Sharp & Dohme Corporation Novel cationic lipids with short lipid chains for oligonucleotide delivery
CN107028886A (zh) 2009-11-04 2017-08-11 不列颠哥伦比亚大学 含有核酸的脂质粒子及相关的方法
NZ700688A (en) 2009-12-01 2016-02-26 Shire Human Genetic Therapies Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
US8808982B2 (en) 2009-12-07 2014-08-19 Cellscript, Llc Compositions and methods for reprogramming eukaryotic cells
TR201906255T4 (tr) 2009-12-11 2019-05-21 Pfizer Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar.
JP6175237B2 (ja) 2009-12-15 2017-08-02 ファイザー・インク コルチコステロイドを含む治療用ポリマーナノ粒およびそれを製造かつ使用する方法
JP5898627B2 (ja) 2009-12-15 2016-04-06 バインド セラピューティックス インコーポレイテッド エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法
US9295649B2 (en) 2009-12-15 2016-03-29 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
WO2011078037A1 (ja) 2009-12-21 2011-06-30 国立大学法人広島大学 老化マーカー、老化抑制物質の評価方法および癌抑制剤
JP2011130725A (ja) 2009-12-25 2011-07-07 Contig I:Kk Ｌｎａオリゴヌクレオチドとそれを含有する化粧品
US20110171248A1 (en) 2010-01-08 2011-07-14 Selecta Biosciences, Inc. Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines
US9670487B2 (en) 2010-01-22 2017-06-06 Sirna Therapeutics, Inc. Cationic lipids for oligonucleotide delivery
WO2011104032A1 (en) 2010-02-26 2011-09-01 Qiagen Gmbh Method for isolating rna from a rna and dna containing sample
US20110218170A1 (en) 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
EP2547345A1 (en) 2010-03-18 2013-01-23 Merck Sharp & Dohme Corp. Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
EP3391877A1 (en) 2010-04-08 2018-10-24 The Trustees of Princeton University Preparation of lipid nanoparticles
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
CA2832672A1 (en) 2010-04-16 2011-10-20 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
EP2377938A1 (en) 2010-04-16 2011-10-19 Eukarys Capping-prone RNA polymerase enzymes and their applications
CA3122219A1 (en) 2010-04-16 2011-10-20 The Children's Hospital Corporation Sustained polypeptide expression from synthetic, modified rnas and uses thereof
US20130260460A1 (en) 2010-04-22 2013-10-03 Isis Pharmaceuticals Inc Conformationally restricted dinucleotide monomers and oligonucleotides
EP2575895A2 (en) 2010-05-24 2013-04-10 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
CA2800728C (en) 2010-05-28 2020-10-27 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
WO2011153120A1 (en) 2010-06-04 2011-12-08 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
RS63817B1 (sr) 2010-07-06 2023-01-31 Glaxosmithkline Biologicals Sa Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE058361T2 (hu) * 2010-08-31 2022-07-28 Glaxosmithkline Biologicals Sa Pegilált liposzómák immunogént kódoló RNA bejuttatására
EP3144015B1 (en) 2010-09-20 2021-06-02 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
CN103260611A (zh) 2010-09-30 2013-08-21 默沙东公司 用于寡核苷酸递送的低分子量阳离子脂质
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013086505A1 (en) 2011-12-09 2013-06-13 Vanderbilt University Integrated organ-on-chip system and applications of the same
US8898864B1 (en) 2010-10-08 2014-12-02 David Porter Integrated rockably released leverage snap fastening system
KR20130124308A (ko) 2010-10-21 2013-11-13 머크 샤프 앤드 돔 코포레이션 올리고뉴클레오티드 전달을 위한 신규 저분자량 양이온성 지질
US20150056300A1 (en) 2010-10-22 2015-02-26 Bind Therapeutics, Inc. Therapeutic nanoparticles with high molecular weight copolymers
EP2635265B1 (en) 2010-11-05 2018-04-04 Sirna Therapeutics, Inc. Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
US20120121718A1 (en) 2010-11-05 2012-05-17 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
US8987377B2 (en) 2010-11-19 2015-03-24 Alnylam Pharmaceuticals, Inc. Poly(amide) polymers for the delivery of oligonucleotides
WO2012082574A1 (en) 2010-12-17 2012-06-21 Merck Sharp & Dohme Corp. Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides
US20120171229A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
WO2012094304A1 (en) 2011-01-04 2012-07-12 Brown University Nanotubes as carriers of nucleic acids into cells
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
DE102011082231A1 (de) 2011-01-12 2012-07-12 Robert Bosch Gmbh Zündspule, insbesondere für kleinbauende Motoren
WO2012099805A2 (en) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
WO2012138530A1 (en) 2011-04-04 2012-10-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides
AU2012255913A1 (en) 2011-05-17 2013-11-21 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof for non-human vertebrates
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
US20140113376A1 (en) * 2011-06-01 2014-04-24 Rotem Sorek Compositions and methods for downregulating prokaryotic genes
US8846883B2 (en) 2011-08-16 2014-09-30 University Of Southhampton Oligonucleotide ligation
US20130046083A1 (en) 2011-08-16 2013-02-21 Tom Brown Oligonucleotide ligation
US20130058977A1 (en) 2011-09-06 2013-03-07 Selecta Biosciences, Inc. Compositions and methods related to induced tolerogenic dendritic cells externally loaded with mhc class i-restricted epitopes
WO2013036748A1 (en) 2011-09-09 2013-03-14 Berry, Lana, L. Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides
WO2013039857A1 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
WO2013039861A2 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
US9579338B2 (en) * 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
EP2773326B1 (en) 2011-11-04 2019-02-20 Nitto Denko Corporation Method for sterilely producing lipid-nucleic acid particles
WO2013071047A1 (en) 2011-11-11 2013-05-16 Children's Medical Center Corporation Compositions and methods for in vitro transcription of rna
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
US9061063B2 (en) 2011-12-07 2015-06-23 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2013086502A1 (en) 2011-12-09 2013-06-13 President And Fellows Of Harvard College Organ chips and uses thereof
WO2013086486A1 (en) 2011-12-09 2013-06-13 President And Fellows Of Harvard College Integrated human organ-on-chip microphysiological systems
CA2858884A1 (en) 2011-12-12 2013-06-20 The Trustees Of The University Of Pennsylvania Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections
WO2013130161A1 (en) 2011-12-14 2013-09-06 modeRNA Therapeutics Methods of responding to a biothreat
WO2013090186A1 (en) 2011-12-14 2013-06-20 modeRNA Therapeutics Modified nucleic acids, and acute care uses thereof
US20140349320A1 (en) 2011-12-15 2014-11-27 The Trustees Of The University Of Pennsylvania Using Adaptive Immunity to Detect Drug Resistance
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
EP2793906A4 (en) 2011-12-21 2016-01-13 Moderna Therapeutics Inc METHOD FOR INCREASING THE LIFE-LIFE OR DURABILITY OF AN ORGAN OR ORGAN EXPLOITATE
WO2013101690A1 (en) 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
DK3421601T3 (da) 2011-12-30 2020-02-24 Cellscript Llc Fremstilling og anvendelse af in-vitro-syntetiseret ssRNA til indføring i pattedyrceller med henblik på at inducere en biologisk eller biokemisk effekt
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
US20150030576A1 (en) 2012-01-10 2015-01-29 Moderna Therapeutics, Inc. Methods and compositions for targeting agents into and across the blood-brain barrier
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
CN103325662B (zh) 2012-03-21 2016-03-30 清华大学 半导体性单壁碳纳米管的制备方法
CA2868391A1 (en) 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
US20150050354A1 (en) 2012-04-02 2015-02-19 Moderna Therapeutics, Inc. Modified polynucleotides for the treatment of otic diseases and conditions
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP2647426A1 (en) 2012-04-03 2013-10-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Replication of distributed nucleic acid molecules with preservation of their relative distribution through hybridization-based binding
US20150150996A1 (en) 2012-06-06 2015-06-04 Northwestern University Compositions and methods for antigen-specific tolerance
EP3884949A1 (en) 2012-06-08 2021-09-29 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
IL307735A (en) * 2012-12-12 2023-12-01 Broad Inst Inc Systems engineering, methods and optimal guiding components for sequence manipulation
AU2013359199C1 (en) 2012-12-12 2021-06-17 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
US20150315541A1 (en) 2012-12-13 2015-11-05 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
JP2016504050A (ja) 2013-01-17 2016-02-12 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
US20160030527A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Compositions and Methods for Treatment of Stroke
JP6567494B2 (ja) 2013-03-14 2019-08-28 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ４’−チオ−修飾ヌクレオチドを有するリボ核酸及び関連方法
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
US20140273230A1 (en) * 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
WO2014165825A2 (en) 2013-04-04 2014-10-09 President And Fellows Of Harvard College Therapeutic uses of genome editing with crispr/cas systems
WO2015006498A2 (en) 2013-07-09 2015-01-15 President And Fellows Of Harvard College Therapeutic uses of genome editing with crispr/cas systems
SMT202100691T1 (it) 2013-07-11 2022-01-10 Modernatx Inc Composizioni 5 comprendenti polinucleotidi sintetici che codificano proteine correlate a crispr e sgrna sintetici e metodi d'uso
MX2016002044A (es) 2013-08-16 2016-08-17 Rana Therapeutics Inc Composiciones y metodos para modular el acido ribonucleico.
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015038892A1 (en) 2013-09-13 2015-03-19 Moderna Therapeutics, Inc. Polynucleotide compositions containing amino acids
GB201317301D0 (en) 2013-09-30 2013-11-13 Linnarsson Sten Method for capturing and encoding nucleic acid from a plurality of single cells
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052479A4 (en) 2013-10-02 2017-10-25 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015051169A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015058069A1 (en) 2013-10-18 2015-04-23 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems
WO2015070413A1 (zh) 2013-11-14 2015-05-21 深圳智慧能源技术有限公司 陶瓷热屏蔽片及耐热结构
EP3076994A4 (en) 2013-12-06 2017-06-07 Modernatx, Inc. Targeted adaptive vaccines
EP3053585A1 (en) 2013-12-13 2016-08-10 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
CN105874072A (zh) 2013-12-30 2016-08-17 库瑞瓦格股份公司 人工核酸分子
EP3092250A4 (en) 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
PT3134131T (pt) 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
EP3157572A4 (en) 2014-06-19 2018-02-14 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015196118A1 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
JP2017522028A (ja) 2014-07-16 2017-08-10 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 環状ポリヌクレオチド
US20170348415A1 (en) 2014-09-03 2017-12-07 Moderna Therapeutics, Inc. Tolerogenic compositions and methods
EP3461904A1 (en) 2014-11-10 2019-04-03 ModernaTX, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
WO2016118724A1 (en) 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
EP4349404A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines

Also Published As

Publication number Publication date
AU2014287009A1 (en) 2016-02-11
US11027025B2 (en) 2021-06-08
PL3019619T3 (pl) 2022-01-10
AU2021200486A1 (en) 2021-02-25
US20220111079A1 (en) 2022-04-14
RS62529B1 (sr) 2021-11-30
EP3971287A1 (en) 2022-03-23
PT3019619T (pt) 2021-11-11
JP2020108379A (ja) 2020-07-16
JP2022164843A (ja) 2022-10-27
CA2917348A1 (en) 2015-01-15
SMT202100691T1 (it) 2022-01-10
AU2014287009B2 (en) 2020-10-29
EP3019619A4 (en) 2017-01-11
JP7019233B2 (ja) 2022-02-15
DK3019619T3 (da) 2021-10-11
WO2015006747A3 (en) 2015-04-23
CY1124740T1 (el) 2022-07-22
JP7225456B2 (ja) 2023-02-20
SI3019619T1 (sl) 2021-12-31
AU2021200486B2 (en) 2023-08-31
HUE056760T2 (hu) 2022-03-28
JP2016523564A (ja) 2016-08-12
JP2022115896A (ja) 2022-08-09
EP3019619B1 (en) 2021-08-25
US20160367702A1 (en) 2016-12-22
HRP20211563T1 (hr) 2022-01-07
EP3019619A2 (en) 2016-05-18
WO2015006747A2 (en) 2015-01-15
LT3019619T (lt) 2021-12-10
JP7136826B2 (ja) 2022-09-13

Similar Documents

Publication Publication Date Title
JP7225456B2 (ja) ＣＲＩＳＰＲ関連タンパク質をコードする合成ポリヌクレオチドおよび合成ｓｇＲＮＡを含む組成物ならびに使用方法
EP2970987B1 (en) Compositions and methods of altering cholesterol levels
AU2014329452B2 (en) Polynucleotides encoding low density lipoprotein receptor
WO2016164762A1 (en) Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
AU2017219054A1 (en) Signal-sensor polynucleotides for the alteration of cellular phenotypes
AU2014329452A1 (en) Polynucleotides encoding low density lipoprotein receptor
EP3058082A1 (en) Compositions and methods for tolerizing cellular systems
HK40070836A (en) Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
HK1224700B (en) Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
HK1220489B (en) Compositions and methods of altering cholesterol levels